Item

REV1 inhibition elicits differential response to cancer therapy

Crompton, Andrew
Citations
Altmetric:
License
License
Abstract
Developing methods to target resistance mechanisms is an important avenue in cancer research. A DNA damage tolerance pathway, translesion synthesis (TLS), contributes to resistance through bypassing DNA damage caused by genotoxic therapies. TLS inhibition is an emerging area of research, and it has been shown that REV1 inhibition, a TLS polymerase, sensitizes cancer cells to cisplatin treatment. In this study, we address whether REV1 inhibition similarly sensitizes cancer cells to radiation therapy. We found that REV1 inhibition confers radioresistance and triggers autophagy. These findings present REV1 as a modulator of response to cancer therapy and warrants further investigation
Description
Date
2023-01-01
Student Status
Undergraduate
Journal Title
Journal ISSN
Volume Title
Type of presentation
Poster Presentation
Collections
UVM Student Research Conference
Show all metadata
Research Projects
Organizational Units
Journal Issue
Citation
URI
https://hdl.handle.net/20.500.14849/8592
DOI
Advisor(s)
Nimrat Chatterjee
Kanayo Ikeh
Department
Program/Major
Microbiology
College/School
College of Agriculture and Life Sciences
Patrick Leahy Honors College
Organization
item.page.researchcategory
Life Sciences
Embedded videos